Vascular-targeting agent

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.^[1]

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
vadimezan (ASA404)

Clinical trials[edit]

Phase II : ZD6126, CA4P, plinabulin (NPI-2358)^[2]^[3]^[4]

Phase III : DMXAA (ASA404).

References[edit]

↑ "Vascular Targeting Agents as Cancer Therapeutics".2004;Full text.
↑ NPI-2358(link). {{{website}}}. clinicaltrials.gov.
↑ Monica M. Mita."Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas".Clin Cancer Res.2010;16(23)
5892–5899.doi:10.1158/1078-0432.CCR-10-1096.PMID:21138873.
↑ Staff."Clinical Trials Update".Genetic Engineering & Biotechnology News.2009;29(8)
58.

This medical article is a stub. You can help WikiMD by expanding the page.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

[1] "Vascular Targeting Agents as Cancer Therapeutics".2004;Full text.

[2] NPI-2358(link). {{{website}}}. clinicaltrials.gov.

[3] Monica M. Mita."Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas".Clin Cancer Res.2010;16(23)
5892–5899.doi:10.1158/1078-0432.CCR-10-1096.PMID:21138873.

[Staff2009-4] Staff."Clinical Trials Update".Genetic Engineering & Biotechnology News.2009;29(8)
58.

[1]

[2]

[3]

[4]